Regeneron Pharmaceuticals Inc (REGN)
Underlying price
$798.48+1.74% today
Stock stats
- Market cap
- $80.8B
- Previous close
- $784.85
- Open
- $786.03
- Day's range
- $779.96 – $801.44
- 52-week range
- $541.00 – $859.34
- Volume
- 338K
- Avg volume
- 713K
- P/E ratio
- 18.67
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Ticker
- REGN
- Asset class
- Equity
- Tokenized by
- 1 issuer
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Employees
- 15,410
- Website
- regeneron.com
Regeneron Pharmaceuticals Inc FAQ
REGN is Regeneron Pharmaceuticals Inc stock, issued on Solana as a token that tracks the listed share. Each issuer mints its own version, so Regeneron Pharmaceuticals Inc trades here as one token.